Expert Pitch
University of Michigan

Why are US drug prices so high? What should a presidential policy to lower drug costs include?

10-Nov-2020 1:55 PM EST, by University of Michigan


Newswise — The high price of prescription drugs is an important issue for voters, and in the past 50 years, Congress and the president have made little headway in restraining costs.

John Clark

John Clark

John Clark, clinical associate professor at the College of Pharmacy and director of pharmacy services at Michigan Medicine, and Amy Thompson, clinical associate professor at the College of Pharmacy and director of ambulatory clinical pharmacy practices at Michigan Medicine, discuss why drug prices are high in the United States relative to other countries, and what can be done to lower them.

Amy Thompson

Amy Thompson

We hear a lot about high retail drug prices. Are high prices also a problem for inpatient drugs?

Clark: Yes, an enormous problem, risking solvency of health systems. When drug companies decide pricing, they need to consider the value of the products in terms of the increased health provided to patients. Most times, the patient’s health is only marginally improved at an incredible cost.

President Trump has issued several executive orders to lower drug prices. Has this helped?

Thompson: At this point, it is too soon to tell. The bulk of the executive orders are aimed to impact Medicare programs only, so it will likely not impact private plans. One of the orders would force rebates typically paid to plans to be passed on to beneficiaries, and there is concern that this would then drive up health plan premiums. The Health and Human Services secretary has been charged with implementing this EO while not increasing federal spending, so I think it will be some time before we can see how this will roll out.

Another EO aimed at lowering the costs of insulin and epinephrine will have a direct impact on federally qualified health centers who provide care to underserved areas. This EO will make insulin and epinephrine costs cheaper for low-income individuals. The definition of low-income will determine the impact of this EO. Attempting to mitigate costs on a drug by drug strategy, such as insulin and epinephrine only, will likely create confusion and administrative costs.

If a presidential candidate were serious about lowering drug prices, what would that policy look like?

Thompson: A policy focusing on transparency across the board will help impact drug costs. Currently, there is nontransparency contracting in place, typically at the manufacturer and pharmacy benefit manager level, which prohibits sharing of pricing and negotiating. In October, the Supreme Court began to hear arguments in the Rutledge v. Pharmaceutical Care Management Association case, which stems from a 2015 law in Arkansas that prohibited pharmacy benefit managers from reimbursing local pharmacies at a lower rate than what the pharmacies pay to fill prescriptions.

Additionally, shifting to a model that holds manufacturers accountable for negotiating to a fair price, for example with the government for Medicare Part D medications, would be important. One model proposed includes competitive licensing, which would allow another manufacturer to bring a generic or biosimilar agent to market before patent expiration, while paying a royalty to the patent holder. This could potentially give more bargaining power.

The president would need to work with Congress to develop strategies where costs are in line with the value the medication provides, rather than arbitrarily set. Congress and the president would need to work with pharma to come to an agreement that limits returns and requires reinvestment. Consideration of executive pay in pharma would also be an opportunity. CEO pay continues to increase as do health care costs, and there is a continued push for more disclosure from the major pharma and biotech firms.

What are the main reasons drugs are so much more expensive for consumers and hospitals in the U.S.?

Clark: There are many economic factors at work that lead the U.S. to pay two-to-six times more for prescription drugs than other countries. Unfortunately, drug pricing is not very straightforward and there are numerous players involved: manufacturers, wholesalers, insurers, pharmacy benefit managers and pharmacies.

In addition to lack of transparency, the majority of manufacturers spend about the same on marketing and research. Elimination of direct-to-consumer marketing (allowed only in Australia and the U.S.) or reducing health professional marketing could have a significant impact on drug costs.

Also, much of the research and innovation costs for the world are absorbed by the U.S. market. If research and development costs were spread to more of a global market, U.S. drug costs may decrease, and other markets may have increased costs to balance.

High U.S. prices could also result, in part, from this reliance on research and development innovation from the U.S. market. For instance, there is a high reliance on the U.S. research infrastructure for preclinical and clinical trials, which may raise medication costs in the U.S. Due to system complexity and so many intertwined economic factors, we may not be able to know for sure.

The U.S. could consider additional price regulations like many smaller nations have done, but the concern is innovation may be stifled due to the huge impact a U.S. market cost shift could have on the global market. If future profits are expected to drop, investment in future innovation may decrease, so one solution might be to restrict some drug costs or profits and study the effect closely to determine next steps.

Thompson: High drug costs are not the product of one issue, it’s a complex issue that will take time to change. High medication costs are rarely, if ever, due to the pharmacy or pharmacist making money. Medication pricing is a complex system of corporate finances and entities in the beginning and middle of the supply chain gaining wealth.

Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573